Short Bowel Syndrome Market to Grow with a CAGR of 6.24% through 2028

Increasing incidence of short bowel syndrome and rising investment in research and development are factors driving the global Short Bowel Syndrome market in the forecast period 2024-2028.

According to TechSci Research report, “Short Bowel Syndrome Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Short Bowel Syndrome Market stood at USD 805.11 million in 2022 and is anticipated to grow with a CAGR of 6.24% in the forecast period, 2024-2028. Short Bowel Syndrome (SBS) is a rare and complex gastrointestinal disorder characterized by the inadequate absorption of essential nutrients due to the surgical removal of a significant portion of the small intestine. The Global Short Bowel Syndrome Market has witnessed significant growth in recent years, driven by various factors. One of the primary drivers of the Global SBS Market is the increasing incidence of Short Bowel Syndrome. This condition often results from surgical interventions for conditions such as Crohn's disease, intestinal volvulus, or trauma. The rising prevalence of these underlying diseases has contributed to a higher incidence of SBS, thus driving the demand for SBS treatments and therapies.

 Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Short Bowel Syndrome Market.”

Pharmaceutical companies and research institutions have recognized the unmet medical needs of SBS patients, leading to increased investments in research and development. These investments have resulted in the development of new therapies and treatment options, including medications designed to improve intestinal adaptation and reduce dependency on parenteral nutrition.

Increased awareness of Short Bowel Syndrome among healthcare professionals and the general population has led to improved diagnosis rates. As healthcare providers become more familiar with SBS, they are better equipped to identify and manage the condition, thereby increasing the demand for SBS-related products and therapies.

Patients with Short Bowel Syndrome often require enteral and parenteral nutrition support to meet their nutritional needs. The expansion of these markets, along with the development of specialized nutritional products, has been a significant driver of the SBS market. Companies offering enteral and parenteral nutrition solutions have seen increased demand for their products.

The Global Short Bowel Syndrome Market is segmented Drug Class, Distribution Channel and company.

Based on Distribution Channel, the Hospital Pharmacies segment has emerged as the predominant market leader. Hospital pharmacists play a vital role in educating SBS patients about their medications, nutritional requirements, and disease management. This patient-centric approach enhances treatment adherence and fosters better outcomes. Hospital pharmacies collaborate closely with physicians, dietitians, and other healthcare providers to develop comprehensive treatment plans for SBS patients. This multidisciplinary approach ensures that patients receive holistic care.

Based on region, North America segment is expected to grow during the forecast period.  SBS patients in North America benefit from a robust network of patient advocacy groups and support organizations. These groups work tirelessly to raise awareness about the condition, provide resources to patients and caregivers, and advocate for improved access to treatment options. Their efforts have helped create a more favorable environment for SBS research and development. North America's healthcare market is characterized by its vast reach and accessibility. SBS patients in the region have access to a wide range of healthcare providers and treatment options. This accessibility, combined with the region's insurance coverage and reimbursement policies, ensures that SBS patients can access the latest treatments without financial barriers.

The Asia Pacific region is experiencing rapid market growth.The region’s  healthcare ecosystem promotes collaboration among stakeholders. Pharmaceutical companies, research institutions, healthcare providers, and patient advocacy groups frequently collaborate on SBS-related initiatives. This collaborative approach accelerates the pace of research, development, and treatment innovation.

Major companies operating in Global Short Bowel Syndrome Market are:

• 9 Meters Biopharma, Inc.
• Wellspect Healthcare
• Emmaus Life Sciences, Inc.
• Merck KGaA
• Nestle S.A.
• Novartis International AG
• OPKO Health, Inc.
• Oxthera AB
• Pfizer Inc.
• PhaseBio Pharmaceuticals Inc.
• Sancilio and Company, Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Short Bowel Syndrome Market is experiencing notable growth due to a combination of factors, including the increasing incidence of SBS, advances in medical technology, growing awareness and diagnosis rates, rising investments in research and development, regulatory support, patient advocacy, and the expansion of enteral and parenteral nutrition markets.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Short Bowel Syndrome Market By Drug Class ( GLP-2, Glutamine, and Growth Hormone), By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Short Bowel Syndrome Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Short Bowel Syndrome Market.

Contact

Mr. Ken Mathews

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com